After apheresis, either plasma-derived or recombinant human FVIII was administered, typically 100 IU kg−1 every 6 h, or in one exceptional case (BMI > 40), up to 200 IU kg−1 every 6 h. The FVIII dosage could be optionally reduced in cases of satisfactory clinical response and 4–6 h recoveries of 50–80% throughout the treatment cycle. The magnitude of such dose reductions was equal to 20% of the coagulation factor dose administered on the preceding

day. All statistical analyses were performed using the Statistical Package for Social Sciences SPSS, version 16.0 (SPSS, Inc., Chicago, IL, USA). Parametric statistics, the Pearson rank correlation (rs) test were used. The primary study endpoints were the time at which (i) activity of the inhibitor was first undetectable,

(ii) the factor substitution could be discontinued and (iii) the termination of the MBMP treatment without the requirement for further apheresis. Kaplan–Meier analysis Acalabrutinib cell line MG-132 clinical trial was performed to evaluate the time at which these endpoints were reached. The median time to reach these endpoints was calculated on the basis of the associated 95% confidence intervals (95% CI). A total of 67 patients (17 males, 50 females) of AH with high-titre inhibitor levels (>5 BU) were diagnosed in our hospital. Sixty-five patients exhibited life-threatening bleeding (maximum haemoglobin on admission: 8.0 mg dL−1) requiring blood transfusions and intensive care monitoring. In two patients, the clinical bleeding was not life threatening (haemoglobin > 10 mg dL−1). The mean age of the patients was 62 ± 16.8 years (mean ± SD). The mean FVIII level at initial diagnosis and at the beginning

of the MBMP was <2.4% (normal: 70–140%). The mean inhibitor titre was 457 BU mL−1± 1042. The mean activated partial thromboplastin time (APTT) on admission was 57.27 s ± 20.86 (normal range: 22–30 s). FVIII inhibitor titres, but not FVIII concentrations correlated with the APTT prolongation (rs = 0.300, P < 0.05) The types of bleeding observed included muscle bleeding (n = 67) associated with compartment syndrome (n = 6), gastrointestinal bleeding find more (n = 1), retroperitoneal bleeding (n = 16), retropharyngeal bleeding, which required artificial respiration (n = 5), and haematuria (n = 3). Underlying diseases were detected in 17 patients. In six women, the inhibitor was diagnosed peripartially (i.e. within 3 months of childbirth). Six patients suffered from other autoimmune diseases (mixed connective tissue disease: n = 4, psoriasis: n = 4, polymyalgia rheumatica: n = 1, Sjögren syndrome: n = 1) and in four patients the inhibitor occurred as paraneoplastic syndrome (lung cancer: n = 1, paraproteinaemia n = 1, lymphoma: n = 1, breast cancer: n = 1). A total of 1099 IA procedures (apheresis) were carried out with an average of 19 apheresis sessions (median: 16, range: 8–62) per patient. The extracorporeal treatment was well tolerated.